Altach is an NLC venture company. At Altach our goal is to become the gold standard in regenerative cartilage technology. We are building a portfolio of biomimetic cartilage grafts allowing surgeons to repair cartilage defects and restore patient’s quality of life. Altach is developing a portfolio of biomimetic cartilage scaffolds utilising Type II collagen which is the building block of native cartilage. The scaffolds are designed to be used stand alone and in conjunction with other cell based therapies. The implants unique composition create a matrix for the patient’s own cells to migrate into and regenerate the cartilage. Medical Devices, …

76 similar entities Type: Startup Activities: deeptech Technologies: Synthetic Biology

Life after cancer exists, we are shaping it! Lattice Medical is a French medtech company pioneering regenerative medicine through tissue engineering and 3D printing technologies. We develop next-generation bioresorbable implants designed to support soft tissue regeneration and improve reconstructive surgery outcomes for patients after cancer and other major tissue loss. By combining biomaterials science, additive manufacturing and medical innovation, we create solutions that work with the body’s own healing mechanisms to enable more natural reconstruction approaches. Our technologies include: • MATTISSE a 3D-printed bioresorbable implant for breast reconstruction after mastectomy, designed to guide autologous tissue regeneration before gradually resorbing • …

75 similar entities Type: Startup Activities: deeptech healthtech manufacturing Technologies: 3D Printing Synthetic Biology

Using mesenchymal stem cells to produce therapeutically meaningful extracellular vesicles. We are a recently incorporated limited company, spun out from the University of York from the Genever lab (www.geneverlab.info), which has over 20 years of experience in cell biology and regenerative medicine. We focus on musculoskeletal regeneration using mesenchymal stem cells (MSCs), with a view to translate our body of work into cutting edge therapeutics. Our current focal point is the field of extracellular vesicles (EVs), which have recently gained substantial traction as a next-generation therapeutic modality. We believe that current approaches have room for improvement in terms of consistency …

93 similar entities Type: Startup Activities: biotech healthtech Technologies: Synthetic Biology

BIOMOLECULES NOW, FOR YOUR FUTURE KYLYS is a Life Science Spin-off from the University of Geneva, now ready to step into clinical development. Passionate about science and biotechnology, we are committed to developing a unique technology to deliver highly effective and safe products based on the next generation of hyaluronic acid (HA). Our products are aesthetic (KYLYS Aesthetics) and medical (KYLYS). Our technology can revolutionize HA delivery for medical and surgical needs, in the field of: Aesthetic Rheumatology Reconstructive surgery Drug delivery system Veterinary

90 similar entities Type: Startup Activities: deeptech healthtech Technologies: Synthetic Biology

Return to your active lifestyle after a six weeks treatment with the KneeReviver and postpone knee replacement surgery! The KneeReviver unloads the damaged knee joint by putting the knee joint surfaces on a short distance. With this temporary unloading treatment the pain reduces, mobility improves and the knee joint tissues may regenerate.

53 similar entities Type: Startup Activities: healthtech

Plant-based Nanotechnologies for autoimmune diseases diagnoses and therapy DIAMANTE (Nano-Technologies for Autoimmune Disease) is a biotech company focused on the use of plants for producing high value-added molecules. The company was funded in 2016 with the development of new tools in autoimmune disease diagnosis and now we are growing approaching therapeutics applications. As an innovation-oriented female company, our value proposition is the creation of novel therapeutic approach for autoimmune diseases based on the restoration of self-tolerance, using plant viruses displaying immunodominant peptides. Diamante, thanks to the Regione Veneto and particularly though the national grant POR FESR AZIONE 1.1.1 2020/2021, has …

125 similar entities Type: Startup Activities: nanotech biotech deeptech healthtech Technologies: Synthetic Biology

NanoMedSyn develops a new delivery platform to create first-in-class drugs by the engineering with patented AMFA vectors NanoMedSyn was born from the fundamental research of its biologist and chemist founders who discovered a breakthrough technology for drug delivery to the lysosomal cell compartment leading to potentiation of therapeutics. This technology, validated at the preclinical level, has a wide range of applications in the fields of oncology, immunity, inflammation or metabolism. NanoMedSyn’s development plan is based on a strong intellectual property of patented synthetic derivatives called AMFA. The main application is the engineering of recombinant proteins like antibodies or enzymes for …

175 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Redefining where cancer treatment begins. Lithea is a life science company with focus on hindering tumor progression and impeding metastasis. Our novelty lies in a protected carrier platform for cancer therapy using hydroxyapatite for local drug delivery. In Lithea, we are committed to developing innovative targeted oncological treatment.

61 similar entities Type: Startup Activities: healthtech deeptech biotech Technologies: Synthetic Biology

Amplio Pharma is a novel and exciting product company developing improved versions of already great drugs. Amplio Pharma is a novel and exciting product company developing improved versions of already great drugs. Amplio Pharma is a privately owned wholly women founded pharmaceutical company. Our vision is to develop and apply modern-day technology to fix the short-comings from drugs that otherwise have a proven track record in their disease area. Our first development candidate, NovoBioJect (AMP101), is being developed to boost the responder rate to current 1st line RA treatment from ca 35% to up to 70%. We intend to reach …

120 similar entities Type: Startup Activities: deeptech biotech Technologies: Synthetic Biology

Bioceltix is changing the veterinary therapy standards. We develop innovative biopharmaceuticals based on stem cells. Bioceltix is a Wrocław-based and internationally oriented biotechnological company developing innovative, both stem cells and secretome based products, for companion animals. Our flagship technology for manufacturing biopharmaceuticals for veterinary use utilizes the therapeutic potential of allogeneic stem cells (one donor – many recipients). Owning a GMP production facility, we provide single technology for several species, diseases, and routes of administration. Our cutting-edge approach will allow the product to be batch-produced and ready for off-the-shelf sale. The veterinary medicines, based on the immunomodulatory mechanism of action …

231 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Developing first-in-class therapies designed to defeat chronic inflammation and fibrosis at the source. Our innovative therapeutic approach targets upstream amplifiers of disease offering potential treatments across a diverse array of therapeutic indications. Calluna Pharma is a clinical stage biotech company driven by a commitment to improve patient outcomes in diseases where existing treatments are sub-optimal. We believe in the power of immunology to push boundaries, challenge the status quo, and develop therapies that will make a real difference for people living with serious diseases.

202 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Bone targeted delivery concept Atlanthera is a drug discovery company focused on bone diseases and bone cancer treatments Our vision: Be the leader in bone-targeted drug delivery to cure bone cancer and metastases Atlanthera can rely on a very high-qualified Team and a worldwide-known experts network Our concept: Bone-targeted delivery of anti-cancer drug www.atlanthera.com Watch our concept in video > https://youtu.be/m3BBWguO6hs Durg discovery, Bone-targeted drug delivery, Bone cancer, and Bone metastases

91 similar entities Type: Startup Activities: deeptech biotech Technologies: Synthetic Biology

Your strategic one-stop-shop partner. Your device, our care. Selenium Medical is a CDMO fully dedicated to medical devices and pharmaceutical applications. Behind every project lies a shared ambition: improving patients’ quality of life and well-being around the world. Certified to ISO 13485 and registered with the FDA and ANVISA, we support medical device manufacturers and healthcare professionals across the entire value chain, from co-development to market launch, through an integrated and tailored service offering. Our multidisciplinary teams combine technical expertise, regulatory know-how and a strong commitment to quality to deliver solutions tailored to the most complex projects, while ensuring reliability, …

445 similar entities Type: Startup Activities: deeptech healthtech manufacturing Technologies: Synthetic Biology

Making the promise of gene therapy a reality Nanogenics is a UK research based virtual biotechnology company. Founded to develop the LipTideTM nanoformulation platform, the focus now is on developing product ECP105 through preclinical and towards clinical testing. ECP105 is under development for the treatment of Glaucoma patients undergoing trabeculectomy surgery. This surgical technique relieves intra-ocular pressure by creating a channel into which the eye drains. Although well established and successful, surgical failure can occur if the surgical wound undergoes fibrosis and the scar prevents drainage. The active ingredient of ECP105 is an siRNA designed to down-regulate a gene involved …

61 similar entities Type: Startup Activities: deeptech biotech Technologies: Synthetic Biology

Biomedical Tissues is specialised in the research and development of implantable medical devices for the regeneration of human tissue. We have invented a novel way to produce microfibers of synthetic biodegradable polymers which can be used as tissue regenerative guides. These devices mimic the structure of collagen fibers offering a 3D environment for cell colonization and proliferation for tissue healing. Our first product to market is Tisseos, a new resorbable synthetic membrane for dental implantology and periodontology. Biomedical Tissues also offers implantable biomaterial and medical device testing and evaluation services for cardiovascular, dental and orthopaedic implants, osteoinductive materials, tissue engineering …

82 similar entities Type: Startup Activities: biotech deeptech healthtech Technologies: Synthetic Biology

LaNua Medical Limited is a MedTech company focused on developing solutions in the Embolization space for Interventional Radiologists worldwide. We are building our team and have exciting roles in R&D and Quality. Medical Devices and Embolization

203 similar entities Type: Startup Activities: deeptech healthtech Technologies: Synthetic Biology

Using cryotherapy to stabilize vulnerable plaque and reduce the risk of heart attack CryoTherapeutics has developed a novel, minimally invasive, catheter-based cryotherapy system (CTS) engineered to address an unmet need in cardiology: the treatment of coronary vulnerable plaque (VP), a leading cause of myocardial infarction (MI), that often leads to fatal events. CryoTherapeutics’ technology is designed to deliver localized cryotherapy to vulnerable plaques, cooling the plaques to temperatures between -10 to -20° C. The cryotherapy aims to stabilize the vulnerable plaques by reducing inflammation and increasing the fibrous cap thickness, hence lowering the risk of rupture and preventing future MI. …

123 similar entities Type: SMB Activities: deeptech biotech Technologies: New Materials

A New Hope for Hemorrhagic Stroke Op2Lysis develops new treatments for patients suffering from thrombosis at the cerebrovascular level, with an initial focus on the hemorrhagic form of stroke. Indeed, there is no currently approved and available therapeutic solution for these patients. The company develops its game-changing NANOp2Lysis platform, associating a breakthrough vectorisation technology, industrial know-how enabling clinical quality production, and preclinical expertise to propose predictive and translational models, a first in this field. O2L-001, the first product resulting from this technology, will soon enter regulatory toxicology with the aim of applying for clinical trial authorisation in patients in North …

234 similar entities Type: Startup Activities: biotech deeptech healthtech Technologies: Synthetic Biology

Stromacare is a pioneer in tumoral stroma immuno-modulation and develops a therapeutic mAb for the treatment of cancers StromaCare is opening a new therapeutic avenue by targeting the tumoral Stroma, which is known to play a key role in several solid cancers, with the objective to be essential in the numerous anticancer protocols of treatment. Stromacare won the Beatrice Denys Foundation 2021 Prize (Foundation for Medical Research). The company is located in Lyon, France. oncology and monoclonal antibody

77 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Biopharmaceutical company performing discovery, rational design and initial clinical development of new MLT-based drugs. Laminar Pharma is a pioneering biopharmaceutical company that focuses on the discovery, rational design and development of a new generation of medicines that act through the innovative therapeutic strategy known as “Membrane-Lipid Therapy” (MLT). Laminar Pharma arose in 2006 as an academic spin-off to commercially develop new scientific know-how and applications generated by leading scientists at the University of the Balearic Islands (UIB) in Mallorca, Spain, headed by Prof. Pablo V. Escriba. Laminar Pharma aims to develop next-generation medicines, nutraceutical and cosmetic products based on the …

59 similar entities Type: SMB Activities: biotech deeptech Technologies: Synthetic Biology

Clinical-Stage Biotech Advancing Mechanism-Driven Wound Healing SolasCure is developing a dual-action therapeutic to address one of healthcare’s most persistent challenges: chronic wounds. An estimated 100 million people worldwide suffer from chronic wounds. Many fail to heal, and those that do often take months, with recurrence rates remaining high. Despite decades of innovation, overall healing outcomes have changed little. Current standards of care do not consistently address the biological drivers that prevent wounds from progressing toward repair. The burden on patients and healthcare systems is substantial, underscoring the need for mechanism-driven innovation in wound care. Aurase Wound Gel is our clinically …

70 similar entities Type: SMB Activities: healthtech deeptech Technologies: Synthetic Biology

Captor Therapeutics is a publicly-listed (WSE:CTX) innovative drug discovery and development company focused on targeting the undruggable proteome using targeted protein degradation. Our mission is to transform lives of patients suffering from cancer, autoimmunity and neurodegenerative diseases. Our groundbreaking technology is perfectly suited to create new drug candidates with the potential to ease patients' burden and cure conditions that so far have only been poorly treatable. Captor Therapeutics S.A. implements projects co-financed by the European Union. All information about the projects is available at: https://captortherapeutics.com/grant-projects. drug development, biotechnology, and protein degradation

734 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

L'os humain préservé et régénéré BIOBank is a leader providing high-quality bone allografts to surgeons in orthopaedics, maxillofacial, and dental surgery. Our bone grafts are sourced from living donors in France & processed via our perfected Supercrit® technology, providing key advantages to surgeons and patients: - Total viral-inactivation - Maintainance of biomechanical and structural intergrity of the tissue - Availability in various shapes & forms, allowing easy handling during the surgical procedure - High quality bone integration, improving patient recovery BIOBank assure l’ensemble des activités d’une banque de tissus, de la prise en charge des tissus (recueil) à la délivrance …

46 similar entities Type: SMB Activities: healthtech biotech

Bioglass Solutions for Bone Regeneration NORAKER, a French player in regenerative medicine,'s mission is to promote the reconstruction of the bones of patients who have undergone orthopedic or dental surgery. A spin-off from INSA Lyon in 2005, NORAKER innovates with its mastery of a biomaterial with exceptional properties: bioactive glass. NORAKER has been distributing its implants since 2015, with an international presence in more than 40 countries. The company invests in close and regular collaboration with surgeons and healthcare professionals, to always better meet the requirements of the medical environment. NORAKER products find their application in orthopedic, spine, CMF, ENT …

101 similar entities Type: SMB Activities: deeptech healthtech manufacturing Technologies: Synthetic Biology

Tailor-designed drug implants ​for local treatments. Founded by Truffle Capital. PK MED is a pioneering French biotechnology company founded in 2019 in Lyon, France, and supported by Truffle Capital, a leading European venture capital firm specializing in life sciences. We develop innovative biodegradable injectable micro-implants and advanced drug delivery technologies designed to address critical healthcare challenges. Our expertise spans rheumatology and novel cell homing approaches aimed at improving the success of bone marrow transplantation. Built on a team of experienced and passionate experts in pharmaceutical sciences, drug delivery, and biomaterials engineering, PK MED combines scientific excellence with innovation to develop …

98 similar entities Type: Startup Activities: deeptech biotech healthtech Technologies: Synthetic Biology

Pioneering Solutions to Understand, Diagnose, and Treat Bone Conditions​ CompagOs is bringing better bone health to all by empowering researchers to transform discoveries into clinical applications, while enabling physicians to match patients with the right treatments and support faster recovery. At the core of our mission are our biologically relevant and reproducible Bon3OIDTM in vitro bone models, developed using state-of-the-art 3D bioprinting. Leveraging this technology, we are currently focused on developing a blood-based assay to detect bone metastases earlier than existing imaging methods, representing a key step toward advancing bone health. Additionally, we provide comprehensive services to academic researchers and …

70 similar entities Type: Startup Activities: deeptech healthtech Technologies: Synthetic Biology

An innovative solution for medical implants Koatum is a MedTech startup that developed a medical implant coating technology for dental and orthopaedic implants. Koatum prevents inflammation and accelerates bone integration, for a faster, painless recovery. Technology provides opportunity to coat any materials which could not be coated with plasma sputtering due to the high temperatures involved. An inert first layer is ensuring perfect formation between implant and coating. Upper layers, made from hydroxyapatite without the intense heat used in plasma coating, remain bioactive and durable. Technology also provides the ability to implement drug delivery systems. With Koatum technology surgeon can …

Type: Startup Activities: it services Technologies: Synthetic Biology

Reshaping rhBMP-2 Perspectives Relieving suffering and improving quality of life with next-generation orthobiologics. Regenerative Medicine, Biomaterials, Medical devices, Drug delivery, biotechnology, BMP2, Programmed Drug Release, and Instructive Tissue Scaffolds

230 similar entities Type: Startup Activities: deeptech biotech Technologies: Synthetic Biology

Delivery of vision care EyeD Pharma is a clinical stage pharmaceutical company dedicated to improving the life of patients suffering from ophthalmic diseases with unmet medical needs such as glaucoma or dry eye. We develop innovative therapeutic solutions based on sustained release polymeric micro-implants and inserts.

127 similar entities Type: Startup Activities: biotech deeptech healthtech Technologies: Synthetic Biology

Based on an R&D program started in 2005, Orano Med has developed new processes for producing high-purity lead-212 (Pb-212), a rare radioactive isotope. Lead-212 is currently at the heart of promising projects in nuclear medicine to develop new treatments against cancer. The innovative approach, known as targeted alpha therapy (TAT), recognizes and destroys cancer cells while limiting the impact on nearby healthy cells. Macrocyclics, Inc., an Orano Med company, is the global leader in high performance chelating agent technology, offering a broad range of services and products. For more information please visit www.macrocyclics.com. Nuclear Medicine & Nuclear Industry, Biotechnology, Pharmaceutical, …

220 similar entities Type: SMB Activities: biotech deeptech Technologies: Synthetic Biology

Bringing precision to the power of biologics with pioneering use of synthetic nanoclays for regenerative medicine. Renovos Biologics Ltd. (Renovos) is a biotech/medtech company focussed on the development of its patented synthetic nanoclay, RENOVITE®, as a drug delivery platform for regenerative medicine and beyond. Regenerative Medicine, Biomaterials, Drug Delivery, Medical Devices, Pharmaceuticals, Stem Cells, Orthopaedics, and Biotechnology

109 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Regain control with personalized muscle regeneration MUVON Therapeutics is a clinical stage Life Science spin-off from the University of Zurich developing a therapeutic platform for the regeneration of skeletal muscle tissue based on autologous cells, not only repairing damaged tissue but also increasing the regenerative potential of weakened muscles. Our initial area of focus is the treatment of stress urinary incontinence in women, supporting them respectfully throughout their journey to a healthy life.

85 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Multi-target cell and gene therapies for unmet medical needs. Aurealis Therapeutics is a Swiss-Finnish Cell and Gene Therapy Platform Company. Our multi-target cell and gene therapies, based on genetically modified safe lactic acid bacteria, address unmet medical needs: Chronic Wounds - Diabetic Foot Ulcers, Venous Ulcers, Pressure Ulcers - deadly Cancers - Ovarian Cancer, Peritoneal Carcinomatosis - Inflammatory diseases. After successfully completing Phase 1 and Phase 2 clinical studies in Diabetic Foot Ulcer (DFU) with our lead asset AUP-16, we're actively preparing a global DFU Phase 3 study. Other indications will follow In Oncology, we are building on impressive pre-clinical …

193 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Simpler joint replacement surgery. Biomimetic printing technology. OSSTEC is a medical technology company developing the next generation of cementless orthopaedic implants. Our lead product, ASCENT, is a cementless partial knee replacement designed to preserve healthy anatomy, restore natural movement and help patients remain active for longer. It combines advanced 3D-printed, bone-mimetic fixation with a simplified surgical workflow built for modern arthroplasty. Our technology is underpinned by more than a decade of research and developed through close collaboration between engineers, scientists and leading orthopaedic surgeons. We believe the future of partial knee replacement is cementless - and we are building the …

80 similar entities Type: Startup Activities: it services Technologies: Synthetic Biology

Your partner for preclinical research in Osteoarticular diseases, Inflammation, Skin diseases... Atlantic Bone Screen is a leading CRO (« Contract Research Organization ») specialized in high-quality preclinical evaluation services in the field of inflammation, osteoarticular diseases and skin diseases. Thanks to its high expertise, Atlantic Bone Screen evaluates drug candidates, biomaterials (either for orthopedic or dental applications) and ingredients/products for cosmetics and food industry. We provide high-quality services to support the characterization of drug candidates, nutraceuticals, biomaterials,... Located in Nantes, North-West of France and created in 2005, Atlantic Bone Screen puts at your disposal a unique preclinical platform with a …

63 similar entities Type: SMB Activities: biotech deeptech Technologies: Synthetic Biology

#BeyondInnovation #DermalFiller #CYTOSIAL #AestheticMedicine New ideas, new innovations, new ways of thinking for the medical device industry. We are a pharmaceutical company specialized in the discovery, clinical development, production and commercialization of innovative products in the field of regenerative medicine. At Bioxis Pharmaceuticals, we contribute to transform science into groundbreaking medical device that meet doctors need to improve the health and well-being of their patients in the field of dermatology and aesthetic medicine. Medical Device, Dermatology, Aesthetic, Cosmetic surgery, Regenerative medicine, Ultra-pure chitosan, and Hyaluronic Acid

202 similar entities Type: Startup Activities: healthtech manufacturing deeptech biotech Technologies: Synthetic Biology

The synthetic collagen revolution NVH Medicinal world expert in synthetic collagen NVH Medicinal is a biotechnology company based in Dijon, created at the end of 2008, whose mission is based on the treatment of pathologies linked to a collagen deficiency. It develops products derived from collagen, the most abundant protein in the body and whose dysfunctions cause numerous diseases (aging, cardiovascular, inflammatory, neurological diseases, fibrosis, cancer and rare diseases). NVH's ambition is to be recognized as an innovative player in the treatment of collagen-related diseases by becoming one of the world leaders in the development, production and marketing of a …

77 similar entities Type: Startup Activities: deeptech manufacturing Technologies: Synthetic Biology

Cell-specific culture matrices for improved cell functionality BioLamina is a biotechnology company with a scientific base and heritage in matrix biology and cell culture research. It supports scientists who have struggled for decades to grow pluripotent stem cells and other primary cells in the lab. By providing tools for efficient and easy cell culture, BioLamina aims to ease the path towards safe and effective cell therapies and make better cell assays and models for increasing accuracy in drug discovery and development. The power of Biolaminin® substrates, developed by BioLamina, has been demonstrated in numerous publications, and they will continue to …

60 similar entities Type: Startup Activities: deeptech Technologies: Synthetic Biology

Light Activated Therapeutics Lightox has developed a new drug for the treatment of early stage oral cancers. The topically applied formulation allows for specific delivery to the lesion and is activated by a specific wavelength of light.

67 similar entities Type: Startup Activities: deeptech biotech Technologies: Synthetic Biology

Biomorphic Programmable Polymers TISSIUM was founded in 2013 to address one of the most persistent medical challenges since the inception of surgical procedures: to reconstruct damaged tissue and restore its natural function. Since the discovery of our first polymer at the labs of Bob Langer and Jeff Karp at MIT, we recognized the exceptional potential for our technology to revolutionize the field of tissue reconstruction in multiple therapeutic areas. Our unique approach to product development leverages the knowledge gained from the development of our technology platform comprised of proprietary polymers, activation technologies, and delivery devices. We have developed a fully …

151 similar entities Tags: FrenchTech120 Type: Startup Activities: biotech deeptech healthtech Technologies: Synthetic Biology

Changing lives of neuromuscular patients with gene therapy. Atamyo Therapeutics is focused on the development of a new generation of safe and effective gene therapies for neuromuscular diseases. A spin-off of gene therapy pioneer Genethon, Atamyo leverages unique expertise in AAV-based gene therapy and muscular dystrophies from the Progressive Muscular Dystrophies Laboratory at Genethon. Atamyo’s most advanced programs address different forms of limb-girdle muscular dystrophies (LGMD). The name of the company is derived from two words: Celtic Atao which means “Always” or “Forever” and Myo which is the Greek root for muscle. Atamyo conveys the spirit of its commitment to …

59 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

3D matrices for tissue reconstruction Application to breast reconstruction The MAT(T)ISSE project proposes to create a new bioprosthesis, a class 3 implantable medical device, which aims to help the body restore damaged regions following curative surgical interventions. This tissue restoration is carried out through the autologous collection of fat cells (adipose tissue) re-implanted on a synthetic and resorbable lace-type textile structure. The textile structure has a role of maintenance, assistance in the multiplication of implanted fat cells and revascularization. It is coupled with a bioresorbable and personalized 3D shell which delimits the volume to be reconstructed. Ultimately, the resorbable support …

56 similar entities Type: Startup Activities: deeptech Technologies: Synthetic Biology

Pioneering Regenerative Medicine CollPlant is a regenerative and aesthetic medicine company developing innovative technologies and products for tissue regeneration and organ manufacturing. Our revolutionary plant-based technology is the only commercially viable technology for mass production of recombinant human Type I collagen (rhCollagen), which is identical to the collagen produced by the human body. This makes our rhCollagen the ideal building block for regenerative medicine. Leveraging on the unique properties of rhCollagen and biomaterial know-how, we are developing a pipeline of products aimed at 3D bioprinting of tissues and organs and medical aesthetics. Our mission at CollPlant is to deliver ground-breaking …

62 similar entities Type: SMB Activities: biotech deeptech healthtech Technologies: 3D Printing Synthetic Biology

Transforming lives with groundbreaking treatments Coultreon Biopharma's mission (formerly Onco3R Therapeutics) is to develop life-changing medicines for patients affected by chronic inflammatory diseases of high unmet medical needs. The team is leveraging their knowledge and expertise to bring transformative innovations to patients suffering from auto-immune diseases. In this field, there is an urgent need for more convenient oral drugs that can offer greater efficacy with a better safety profile. Drug Discovery, Drug Development, Immunology, Biotech, and R&D

826 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Silk innovation for life sciences KLISBio is a clinical-stage regenerative medicine company. We are developing several innovative technology platforms based entirely on natural silk fibroin, which allow for the creation of various solutions for endogenous tissue repair and regeneration. Silk is one of the most renowned and ancient materials used in medicine. In its raw state, silk consists of two main proteins, sericin and fibroin, with a glue-like layer of sericin coating two singular filaments of fibroin. Silk fibroin is fully biocompatible and promotes cell proliferation by also stimulating in-vivo tissue regeneration. Depending on the technology used, it provides a …

64 similar entities Type: Startup Activities: deeptech biotech Technologies: Synthetic Biology

Treating Neurodegenerative Disease by Restoring Autophagy At Samsara Therapeutics, we’re on a mission to unlock the full potential of autophagy activation in combating age-related neurodegenerative diseases. Our innovative approach aims to delay the progression of several debilitating conditions, offering new possibilities for patients and their families. biotechnology, biopharmaceuticals, rare disease, neurodegeneration, longevity, drug discovery, and drug development

428 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Bringing People & Ressources Together The creation of Genbiotech, a spinoff of the Laboratoires Genévrier results of 15 years of strategic involvement in biotechnological research with one goal: to improve the quality of life of patients in the field of rheumatology, dermatology and aesthetic. We believe that tomorrow medicine needs to be dedicated and targeted to patients. We aim to improve existing treatments by using non invasive processes allowing local and sustained administration of biological and active molécules. The company, incepted in 1998, has currently a staff of 11 people and is located in Sophia Antipolis (South of France). For …

633 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

From replacement to regeneration osteobionix is a company dedicated to advancing the standards of care for people suffering from cartilage or bone loss. Cartilage and bone loss may result from a variety of causes including osteoarthritis, trauma and tumor and can severely affect a person’s lifestyle. osteobionix wants to provide people suffering from cartilage or bone loss with innovative, high quality, proven, customized solutions, which can help them regain the lifestyle they deserve. osteobionix collaborates with surgeons in designing and manufacturing reliable, cost-effective solutions, which take into account the uniqueness and complexity of each single surgical case. osteobionix strives to …

58 similar entities Type: SMB Activities: deeptech manufacturing Technologies: 3D Printing Synthetic Biology

We contribute to a better quality of life with healthcare solutions enabling improved oral health Koite Health is a Finnish health tech company whose innovation, Lumoral®, has already revolutionized dental care in Finland and is quickly expanding in Europe. Lumoral® is an advanced and patented medical device that treats and prevents oral diseases. The company's expert team is composed of high-level professionals with decades of experience in the medical and pharma industries, marketing, and clinical research. The company's scientific board consists of internationally recognized dental professors and researchers. Lumoral is an oral health device used in addition to regular tooth …

61 similar entities Type: Startup Activities: healthtech Technologies: Synthetic Biology

we care for Lymphedema Lymphodys, a biotechnology startup, is dedicated to finding therapeutic solutions for pathologies related to lymphatic vascular system failure. These pathologies lead to alterations in skin, subcutaneous and adipose tissue for which no treatment is currently available on the market. After several years of collaboration between Inserm and University Hospital in Toulouse, a therapeutic solution in gene therapy to treat lymphedema, a chronic, painful and disabling pathology, is emerging. A phase I/IIa clinical trial will be conducted in patients who developed lymphedema after breast cancer. R&D, gene therapy, and lymphoedema

76 similar entities Type: Startup Activities: deeptech healthtech biotech Technologies: Synthetic Biology

🔬 French manufacturer of medical devices based on biopolymer (P4HB) Apha Biomat is part of the Ph Tech group, together with Meccellis Biotech (expert in biologics for Soft Tissue repair). Apha Biomat’s new industrial facility will support Xenopha’s manufacturing operations, alongside with Meccellis. Xenopha is the result of an intensive R&D program aiming at combining Meccellis’ expertise in biologics with a new biopolymer:P4HB. This hybrid combination allows for the design of natural 3D medical devices. Xenopha’s first indication is dedicated to breast reconstruction where a solution to replace silicon is eagerly awaited by patients and surgeons. For any further information, …

119 similar entities Type: Startup Activities: deeptech healthtech manufacturing Technologies: Synthetic Biology

Ilya Pharma 🇸🇪🇺🇸 is bringing local-acting immunotherapies to patients Delivering local-acting immunotherapies to patients ATMP, Gene Therapy, Drug development, Clinical trials, GMP, IBD, Wound treatment, Scar, Topical, Oral, Research, Science, Immunology, Immunophysiology, microbiology, Applied microbiology, Regulatory excellence, Skin, Diabetes, IBD, Cysticfibrosis, SAVI, colitis, Cystic fibrosis, and Inhalation

646 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Shaping the future of regenerative medicine At 4Tissue, we’re pioneering the future of regenerative medicine with innovative hydrogel solutions that support natural tissue restoration. We are an innovation-led research and clinical development organization. Our mission is to redefine the boundaries of tissue reconstruction, regeneration, and anti-aging, utilizing innovative biocompatible and bioresorbable polymers platform The first product, a bioresorbable injectable hydrogel, is focused on a better cell survival and the full regeneration of adipose tissue for breast reconstruction and augmentation applications.

118 similar entities Type: Startup Activities: deeptech biotech Technologies: Synthetic Biology SaaS

Harnessing the healing potential of adenosine for tissue regeneration Privately held company focused on developing and marketing first-in-class regenerative therapies for osteoarthritis. Our proprietary platform technology harnesses the healing potential of the purinergic system which plays a critical role in maintaining cartilage homeostasis. Our lead product is a proprietary formulation for regenerating cartilage in joints with established osteoarthritis, targeting a rapidly growing joint preservation market. Our goal is to offer patients a disease modifying therapy with uncompromising efficacy relative to existing technologies. By developing this disease modifying therapy, we will significantly improve clinical outcomes and patient quality of life, and …

87 similar entities Type: Startup Activities: biotech deeptech healthtech Technologies: Synthetic Biology

The natural solution for drug delivery DelSiTech is a drug delivery and drug development company based in Turku, Finland. DelSiTech has developed a unique proprietary technology making it a world leader in advanced biodegradable silica-based drug delivery. The technology has successfully been applied to the controlled release of small molecules, biopharmaceuticals and viral vectors with a focus on parenteral and local administration. We can work with you from early feasibility testing to clinical proof of concept; the technology can also be licensed to industry partners. With the DelSiTechTMSilica Matrix, we can create novel products, provide alternative administration opportunities, and extend …

86 similar entities Type: SMB Activities: deeptech biotech Technologies: Synthetic Biology

Powering the next wave of genetic medicines through superior delivery ReCode Therapeutics is a clinical-stage genetic medicines company using superior delivery to power the next wave of mRNA and gene correction therapeutics. ReCode’s selective organ targeting (SORT) lipid nanoparticle (LNP) platform is a next-generation, genetic medicines technology that enables precise delivery to target organs and cells beyond the liver. RNA Therapies, Genetic Medicines, Non-Viral Lipid Nanoparticles, Genetic Respiratory Disease, Cystic Fibrosis, Primary Ciliary Dyskinesia, and Biotechnology

148 similar entities Type: Startup Activities: deeptech biotech nanotech Technologies: Synthetic Biology

Qrem Cytokine is the first device with Lab-in-a-box technology able to obtain Autologous Serum Rich in Cytokines Qrem offers the first laboratory device in a box capable of achieving a natural cure for osteoarthritis (OA) by reducing pain by 75% for more than 1 year. Health professionals can have a cytokine-rich autologous serum, ready to cure, in 30 minutes wich can be used for arthritis treatment and pain reduction by intra-articular injection. Cytokine therapy is showing a slowdown in the degenerative process and is presented as a new alternative for the population suffering from osteoarthritis. Regenerative Medicine Therapies, Traumatología, Reumatología, …

64 similar entities Type: Startup Activities: deeptech healthtech

Starting in the mid 1990’s, the founders of Nanovation Partners LLC sponsored research at the University of California at San Diego (UCSD) in the lab of Sungho Jin, PhD. This research showed enhanced osseointegration and reduced implant surface infection by forming thousands of rows of tiny metal oxide nanotubes per square millimeter on the medical implant-to-tissue surface. These nanotubes were formed into the metal oxide surface already present on metal implants. No new materials were formed and no synthetic hydroxyapatite or other coating was needed. The group noticed that nearby stem cells treated the nanotube surfaces more like the outer …

59 similar entities Type: Startup Activities: biotech deeptech manufacturing Technologies: New Materials Synthetic Biology

The Cell Therapy Venture Builder MedXCell is a European cell therapy venture builder with a strong industrial mindset and a global perspective. Our focus is on technologies, techniques or novel applications in major diseases such as cancer, autoimmune, neurological and degenerative disorders. Established in 2018, we have offices in Switzerland, the EU (France) and the US (Cambridge, MA) and a multidisciplinary expert team with entrepreneurial, clinical, operational, business development and funding capabilities. Biotechnology, Cell Therapy, Immunotherapy, NK Cells, Mesenchymal Stromal Cells, Immuno-oncology, and Osteoarthritis

582 similar entities Type: SMB Activities: biotech deeptech Technologies: Synthetic Biology

Innovative Biosurgery Founded in 2005 and based in the Lyon suburb of Saint-Priest (France), Biom’up develops and commercializes hemostatic products based on patented biopolymers designed to simplify traditional and laparoscopic surgical procedures in numerous specialties such as cardiac, general and orthopedic, and give patients a better quality of life. The Company’s lead product, HEMOBLASTTM Bellows, is marketed in Europe and the United States. Biotechnologie, Dispositifs Médicaux Implantables, Collagène, Equipements médicaux, Hémostase, Innovative biosurgery, Medical devices, Hemostasis, Collagen, Biotechnology, Pharmacy, Hemoblast, hemostatic, medical devices, and hemostasis

220 similar entities Type: SMB Activities: deeptech healthtech Technologies: Synthetic Biology

experts in bone regeneration Biomatlante is a specialist in synthetic biomaterials promoting bone regrowth and the precursor of bone substitute technologies. We market our products for orthopedic, trauma, spine, ENT, stomatological and dental surgery in more than 50 countries. Our Mission Develop and promote the proprietary MBCP® Technology as the scaffold of reference in any bone regeneration solution for best-in-class patient care. Our Vision Bone surgeries often demand grafts for which autograft is considered as the gold standard in terms of tissue regeneration performance and limited rejection risk. Autograft is available in limited quantity though, and harvesting methods are expensive …

73 similar entities Type: SMB Activities: healthtech deeptech Technologies: Synthetic Biology

Transforming How Cell Therapies, Biologics, Peptides, and Hormones Are Delivered Likarda is a biotech company developing enabling technologies to transform the way cell therapies are delivered and optimized. Our revolutionary method to coat cells with stealth hydrogels, called Core Shell Spherification® (CSS), protects cells from destruction, keeping them viable while maintaining them in the intended location within the body. Unlike our competitors, Likarda has developed a library of over 50 different hydrogel formulations that work with Core Shell Spherification®, resulting in the ability to uniquely tailor the coating molecules to the specific requirements of the therapeutic cells themselves. From durable …

74 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Transforming Bone Repair The standard of care for healing broken bones hasn't changed in over fifty years. Invasive metal hardware is still routinely used to fixate bones–often with less-than-optimal patient outcomes. RevBio® is a medical device company that has invented TETRANITE®, a regenerative bone adhesive currently in 150 patients across seven FDA approved clinical trials. Our patented “bone glue” is founded upon a comprehensive patent portfolio with global patent protection extending through 2042. Easily injectable into a range of musculoskeletal defects, TETRANITE has demonstrated superior performance over other standard of care options in curing speed and strength, rate of resorption, …

57 similar entities Type: Startup Activities: deeptech healthtech Technologies: Synthetic Biology

We developed a new generation of cell therapy products to regenerate articular cartilage damage: Cartibeads Vanarix has developed a new generation of cell therapy to produce high-quality hyaline cartilage mini-grafts, named Cartibeads, which resemble native tissue. Cartibeads are bio-engineered cartilage implant made from allogeneic chondrocytes. When implanted during minimally invasive arthroscopic surgery, Cartibeads can completely self-integrate into cartilage lesions and thus regenerate the tissue. Cartibeads are designed for the treatment of cartilage defects in traumatic and osteoarthritic joints. #cartilagerepair #cartilageregeneration #celltherapy #kneerepair #osteoarthritis

59 similar entities Type: Startup Activities: deeptech Technologies: Synthetic Biology

Surgical tissue repair At Regenosca, we’re pioneering the future of regenerative medicine with a breakthrough platform that enables the body to heal itself—without synthetic implants or tissue grafts. Our 100% engineered, natural collagen scaffolds guide perfect tissue regeneration, offering a safer and more effective alternative to traditional treatments. With 100% success in urethra reconstruction—our initial indication in urology—demonstrated in a first-in-human trial (sustained at two-year follow-up), we’re proving the potential of our technology to transform tissue restoration across multiple medical fields. Our goal? To make tissue regeneration a reality for patients worldwide, through collaborations with clinicians, researchers, and industry partners. …

70 similar entities Type: Startup Activities: deeptech Technologies: Synthetic Biology

Addressing the problem of natural repair of soft tissues with injectable 3D scaffolds Volumina Medical is a multi-award-winning start-up active in the field of medical devices supported by a solid network of investors. The company develops breakthrough innovations for plastic and reconstructive surgery. The first product is an implantable polymeric biomaterial and targets the regeneration of soft tissue of the human body which are damaged after tumor excision, genetic malformation or trauma. Implants, Biomaterial, and Regenerative Medicine

132 similar entities Type: Startup Activities: deeptech healthtech Technologies: Synthetic Biology

Shockwave Medical is revolutionizing the interventional treatment of advanced cardiovascular disease by developing technology that targets calcified plaque. Inspired by 30-years of safety and efficacy in kidney stone treatment, our Intravascular Lithotripsy family of catheters delivers localized lithotripsy at the site of cardiovascular calcium that enables gentle balloon dilatation of calcified, stenotic arteries. IVL catheters use sonic pressure waves to preferentially impact hard tissue, disrupting calcium, while leaving soft tissue undisturbed. An integrated balloon catheter then dilates the calcified lesion at low-pressure, restoring blood flow. Stay connected with us at www.ShockwaveMedical.com and on Twitter @ShockwaveIVL

62 similar entities Type: Startup Activities: healthtech deeptech Technologies: Synthetic Biology

Changing the paradigm of osteoarthritis treatment! CartilaGen Inc. is developing an intra-articular injection of a small-molecule drug capable of preventing post-traumatic osteoarthritis. CartilaGen's solution aims to provide an unprecedented disease-modifying treatment to an area of medicine that remains an unmet medical need. Osteoarthritis, Biomaterials, and Preventative Medicine

111 similar entities Type: Startup Activities: biotech deeptech healthtech Technologies: Synthetic Biology

Allogeneic Cell Therapy Platform that Leverages Natural Platelet Biology PlateletBio is an allogeneic cell therapy company focused on platelet biology. We are pioneers, discovering a new category in therapeutics. Our approach is one-of-a-kind, recreating nature’s legendary delivery cell. In doing so, we’re developing a cell therapy empowered to tackle previously unmet medical challenges. biotechnology, platelets, and drug discovery

459 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Lumix Laser - Cutting-edge technology - Unique, powerful & versatile Exclusive French distributor for FISIOLINE. Cutting-edge technologies and effective therapeutic protocols for results from the first session. Medical Device, Laser, and Surgery

306 similar entities Type: Startup Activities: healthtech Technologies: Synthetic Biology

Redefine complex wound healing Millions of people live with wounds that won’t heal. These wounds limit mobility, cause pain, and take away independence. Current treatments are often slow, expensive, and frustrating — for patients, caregivers, and healthcare systems alike. At Plasmacure, we’re changing that. Our patented cold plasma system, PLASOMA, is the first solution proven to close chronic wounds faster, safer, and more effectively. Clinically validated In a randomized controlled trial, PLASOMA was shown to be 2.5x more effective than traditional wound care. Cuts costs, boosts efficiency Treatment with PLASOMA can reduce healthcare costs by more than 40% and free …

81 similar entities Type: Startup Activities: healthtech deeptech Technologies: Synthetic Biology

Novadip is transforming the lives of patients using its unique 3M3 tissue regeneration technology platform. Novadip Biosciences is a clinical-stage biopharmaceutical company founded to design, develop, and bring to the market a new class of regenerative tissue products to accelerate healing of large bone defects and injuries in a single treatment. Novadip’s lead allogeneic product, NVD-X3, employs a matrix containing multiple bioactive factors that induce accelerated tissue healing. Designed as an “off-the-shelf” product, NVD-X3 can be shipped and stored at room temperature and offers superior intraoperative handling characteristics. Novadip is also developing NVD-003, an autologous therapy derived from ASCs as …

86 similar entities Type: Startup Activities: biotech deeptech Technologies: 3D Printing Synthetic Biology

OssDsign is a developer and global provider of next-generation bone graft-substitute products. OssDsign is a developer and global provider of next generation orthobiologics products. Based on cutting edge material science, the company develops and markets products that support the body's own healing capabilities, giving patients back the life they deserve. Website: www.ossdsign.com Newsroom: https://news.cision.com/ossdsign-ab (Always consult Instructions for Use which accompany the products for complete indications, contraindications, warnings and precautions.) Medical devices, Bone regeneration, Bonegraft, Orthopaedic surgery, Spine surgery, and Orthobiologics

190 similar entities Type: Startup Activities: healthtech deeptech Technologies: Synthetic Biology

Preparation Manipulation Imaging LLS ROWIAK Laser LabSolutions GmbH develops and provides advanced laser-based systems and services for cutting, imaging, tissue and material processing, and cell manipulation. Our technologies support applications in pharmaceutical and biotechnological research, medical device and implant development, as well as material sciences for testing and quality analysis. Laser Microtome – Innovative Sample Preparation For histopathological studies or in vitro tests involving calcified or mineralized tissue or implanted materials (e.g., bone, dental tissue, cochlea, vascular stents, ceramics, or dental screws), our laser microtome offers an innovative solution for fast and precise sample preparation. Instead of a knife of …

69 similar entities Type: Startup Activities: deeptech biotech Technologies: Synthetic Biology New Materials

Unlock the potential of your drug with our expertise in Transdermal and complex Injectable product development Nemaura Pharma is a private specialist biotech company who have developed several advanced versatile skin drug delivery systems. Our technologies have been designed with clinical needs in mind and are all minimally invasive and very cost-effective. We are strategically positioned to work with global pharmaceutical companies, as well as new biotechnology companies, to successfully bring both new and old drugs to patients in superior delivery formulations and systems. Founded in 2005 Nemaura has its headquarters and laboratory facilities in the United Kingdom at the …

172 similar entities Type: SMB Activities: biotech deeptech healthtech Technologies: Synthetic Biology

CrannMed is developing resorbable embolization technologies CrannMed is a medical technology company developing resorbable embolisation therapies for chronic musculoskeletal conditions. Founded in 2018, CrannMed brings together world-leading expertise across clinical, material science and medical technology to advance next-generation resorbable microspheres designed to deliver therapeutic effect safely. While permanent microspheres have been used for decades in oncology and other embolisation procedures, resorbable embolisation opens new possibilities in musculoskeletal medicine including Knee Osteoarthritis, Adhesive Capsulitis (Frozen Shoulder) and Plantar Fasciitis - conditions affecting millions of patients worldwide. Commercialisation, medical devices, medical device companies, Embolization, Microcatheters, and Peripheral

85 similar entities Type: Startup Activities: biotech deeptech healthtech Technologies: Synthetic Biology

Innovation to enhance bone healing. Our mission is to advance the science of bone regeneration through cutting-edge research and continuous innovation by partnering with researchers and physicians. We provide patients with safe, effective products that treat bone defects and promote healing. Bone regeneration, Orthopaedics, Traumatology, Bone substitute, Innovation, Bone void, Biomimetic and Bioactive bone substitute , and Medical Device

82 similar entities Type: Startup Activities: deeptech healthtech Technologies: Synthetic Biology

A Revolutionary Platform for Regenerative Medicine Our jellyfish collagen-based innovation addresses complex regenerative medical needs, shaping next generation treatments and supporting current and future scientific research. At the heart of our products is marine-sourced Collagen Type 0, an evolutionary ancient stem collagen that is foundational, allowing greater applications across multiple indications. Medical Grade Collagen, Native Collagen, Cell Culture Reagents, Wound Healing, Hydrogels, Non Mammalian Collagen, Collagen, Reagents, Marine Biotechnology, regenerative medicine, 3dscaffolds, collagencoatedplates, and 3dsponges

75 similar entities Type: Startup Activities: deeptech biotech Technologies: Synthetic Biology

Move away from knee pain with our Meniscus Prosthesis. ATRO Medical is a spin-out from DSM and Radboudumc and builds on the knowledge developed in the Public-Private Collaboration BioMedical Materials that started in 2010 with a consortium of universities, private companies and financial support from the Dutch government. The collaboration between the clinical, biomechanical and polymer experts has been instrumental in the development of our Meniscus Prosthesis. Artimis® will be the first anatomically shaped polymer based meniscus implant. Please note, Artimis® is an investigational device in development and is not available for clinical use the coming years. More information can …

60 similar entities Type: Startup Activities: deeptech healthtech

Customized Bioprinting systems and Bioreactors. Creating Life Changing Futures. REGEMAT3D develops customized Bioprinting Systems and Bioreactors - BMAP. We create Living Tissue Technologies. The potential of bioprinting in regenerative medicine and tissue engineering is huge. There are still many problems to be solved and many hypothesis to be tested in order to find solutions to tissue regeneration. Our mission is to develop innovative solutions in the area of bioprinting and regenerative medicine towards the clinical application of this amazing technology, to improve people ́s quality of life. bioprinting, regenerative medicine, biotechnology, and tissue engineering

71 similar entities Type: Startup Activities: biotech deeptech Technologies: 3D Printing Synthetic Biology

NewAmsterdam Pharma Corporation is a clinical-stage biopharma company creating therapies for cardiometabolic diseases. This page is intended for US audiences. Founded in 2019, NewAmsterdam Pharma Corporation is a late-stage clinical biopharmaceutical company focused on the research and development of transformative therapies for cardiometabolic diseases. Its mission is to improve patient care in populations where traditional therapies have been unsuccessful or are not tolerated. The Company is investigating a selective cholesteryl ester transfer protein (CETP) inhibitor as an LDL-C lowering therapy for patients who cannot be treated optimally with currently available lipid-lowering therapy or for patients with Atherosclerotic Cardiovascular Disease/Familial Hypercholesterolemia …

185 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Helping people heal with 3D printed medical devices made from 4Degra®. Regenerative, resorbable and customisable. Parent company of the 4D Group, 4D Medicine Ltd is dedicated to shaping the future of implantable medical devices made from proprietary resorbable biomaterials. The 4D Group’s technology platform is centred around 4Degra®, a patent protected resorbable photocurable resin based on unique polycarbonate urethane chemistry. A result of 15 years rigorous academic research in leading U.K. universities, 4Degra® promises to free resorbable medical device design from historic constraints and overcome the clinical performance issues of current material options. The first medical devices to be made …

60 similar entities Type: Startup Activities: deeptech biotech healthtech Technologies: 3D Printing Synthetic Biology